bioAffinity Technologies (BIAF) Form 8-K Summary

• Filing Date: November 5, 2025
• Registrant Status: BIAF is listed on Nasdaq and classified as an Emerging Growth Company.

Item 8.01 Other Events

The key filing purpose relates to a positive operational update:

• bioAffinity Technologies announced month-over-month growth in CyPath® Lung test volume.

Investors should examine the referenced Exhibit 99.1 (Press Release) for specific quantitative metrics supporting this growth claim, as this report serves only as notification of the announcement.

bioAffinity